Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00853489 · ClinicalTrials.gov registry record · Phase 4
rhBMP-2 Versus Autograft in Critical Size Tibial Defects
A Phase 4 study, sponsored by St. Louis University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT00853489 is a Phase 4 study that was terminated before completion, run by St. Louis University. The registered enrollment target is 33 participants.
The verdict
NCT00853489, a Phase 4 study, was terminated before completion, sponsored by St. Louis University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of our study is to evaluate the use of recombinant human bone morphogenetic protein 2 (RhBMP-2) as compared to standard ICBG in the treatment of severe open tibia fractures with a critical size bone defect (at least one centimeter in length compromising at least 50% of the circumference of the bone).
Interventions
- DEVICE recombinant bone morphogenetic protein 2
- PROCEDURE Autogenous iliac crest bone graft
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2011-08 |
| Est. Completion | 2017-02-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00853489
The ClinicalTrials.gov registry entry for NCT00853489 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Louis University, which has 107 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which recombinant bone morphogenetic protein 2 is the first listed.
NCT00853489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00853489 about?
NCT00853489 is a clinical study titled "rhBMP-2 Versus Autograft in Critical Size Tibial Defects". The purpose of our study is to evaluate the use of recombinant human bone morphogenetic protein 2 (RhBMP-2) as compared to standard ICBG in the treatment of severe open tibia fractures with a critical size bone defect (at least one centimeter in length compromising at least 50% of the circumference ...
What is the current status of trial NCT00853489?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2011-08. Estimated completion is 2017-02-17.
What interventions are being tested in trial NCT00853489?
The interventions under investigation include: recombinant bone morphogenetic protein 2 (DEVICE), Autogenous iliac crest bone graft (PROCEDURE).
Who is sponsoring clinical trial NCT00853489?
This trial is sponsored by St. Louis University, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.